USD 1.27 billion
Liposomal Doxorubicin Market Size, Share, Growth Analysis, By Product(J7J (Doxil/Caelyx), Sun Pharma (Lipodox), and Teva (Myocet)), By Application(leukemia, bone sarcoma, breast cancer, gastric cancer), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35I2216 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
70
|Figures:
75
Liposomal Doxorubicin Market Insights
Global Liposomal Doxorubicin Market size was valued at USD 1.27 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 2.16 billion by 2031, growing at a CAGR of 6.1% in the forecast period (2024- 2031).
The market for liposomal doxorubicin is growing at a significant rate owing to the increased prevalence of sarcoma. Doxorubicin (liposomal) treats breast cancer, ovarian cancer, Kaposi sarcoma, and other malignant tumours. Doxorubicin is an anti-cancer chemotherapy medication in a liposome, a closed lipid sphere. Factors augmenting the growth of this global market include modern healthcare facilities, rising healthcare costs, improved patient awareness of potential therapies, and the rise in generic versions of life-saving medications. However, the increasing generic medication competition and strict FDA requirements for new drug approval could restrain the worldwide liposomal doxorubicin market.
Furthermore, the market would develop profitably due to increased awareness of adequate medicine substitutes and growing investments by public and private key manufacturers. Sales of liposomal doxorubicin are projected to increase significantly due to the failure of earlier systemic treatment for ovarian cancer and Kaposi's sarcoma associated with AIDS. Hepatocellular carcinoma incidence and survival rates are rising, another factor influencing liposomal doxorubicin demand.
US Liposomal Doxorubicin Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024- 2031
Global Market Size
Largest Segment
J7J (Doxil/Caelyx)
Fastest Growth
J7J (Doxil/Caelyx)
Growth Rate
6.1% CAGR
Global Liposomal Doxorubicin Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Liposomal Doxorubicin Market Segmental Analysis
The market is segmented based on product, application, and region. This group is further divided into smaller subdivisions that expand their channels to include various market areas. J7J (Doxil/Caelyx), Sun Pharma (Lipodox), and Teva (Myocet) make up the product category, whereas leukemia, bone sarcoma, breast cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, Kaposi sarcoma, and other applications make up the application category. By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.
Liposomal Doxorubicin Market Analysis by Product
According to product type, J7J (Doxil/Caelyx) is the largest segment and is anticipated to hold the majority of the market during the projected period, growing at a CAGR of 4.9%.
The high consumption, expanded supply chain, and accessibility of its distribution channels, together with an increase in manufacturing facilities globally, are the driving forces behind this segment's sales. The market for liposomal doxorubicin is growing along with chronic disorders including liver and kidney cancer.
Liposomal Doxorubicin Market Analysis by Application
The market for liposomal doxorubicin is dominated by the liver cancer application and is expected to grow at a CAGR of 4.8%. High use of the medicine in the treatment of liver cancer, strong success rate, and rising effective use are the factors influencing this segment's high sales.
Men and women are both developing liver cancer, which has serious health consequences. Liposomal doxorubicin aids in the therapy and gives medical professionals better control over its dosage.
Global Liposomal Doxorubicin Market By product (%)
To get detailed analysis on other segments, Request For Free Sample Report
Liposomal Doxorubicin Market Regional Insights
The largest market is the US, which is expected to expand at a CAGR of 5.2% between 2022 and 2032. In North American nations like the US and Canada, where an unhealthy lifestyle and rising obesity rates are contributing to an increase in cancer cases, the market for liposomal doxorubicin is growing.
By the end of 2032, the area is projected to have a market revenue of USD 743 Mn. The rising number of cancer patients and the usage of cutting-edge medications on them are the driving forces behind the soaring sales of liposomal doxorubicin.
Other than this, China is the market for liposomal doxorubicin that is expanding at the second-highest rate, with a CAGR of 4.8%, and will have the second-highest value of USD 150 Mn by 2032, while the Japan area is expanding with a CAGR of 3.8% between 2022 and 2032, bringing in USD 121.2 Mn. The anticipated value of USD 87 Mn (2028) is also expected to increase in the UK alongside Japan at a CAGR of 4.5% between 2022 and 2028.
Global Liposomal Doxorubicin Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Liposomal Doxorubicin Market Dynamics
Liposomal Doxorubicin Market Drivers
Rise of Breast Cancer Cases to Bolster Market Growth
- One of the primary uses of liposomal doxorubicin is to treat breast cancer, which is increasing at an alarming rate in many nations. The increasing innovation in formulations is one of the main factors raising the drug's popularity and usage to treat breast cancer. These are a few of the elements promoting the market's expansion. Additional factors anticipated to fuel the market in the upcoming years include rising demand for pharmaceuticals used in targeted therapy, increased usage of chemotherapy treatments, and more significant investment by private companies in this application. Government support for the healthcare industry is another crucial element in expanding the market's global reach.
- During the projection period, attractive market opportunities are expected to be generated by ongoing research and development activities to advance technologies.
Liposomal Doxorubicin Market Restraints
Harmful Side Effects to Hinder Market Growth
- It is anticipated that several negative effects of the medicine liposomal doxorubicin may restrain market expansion. Infection risk is increased, dyspnea, a pale complexion, bruises, nosebleeds, weakness before and after treatment, hands and feet that are red, painful, and peeling, weight loss, diarrhea, and weariness are just a few of the side effects.
Request Free Customization of this report to help us to meet your business objectives.
Liposomal Doxorubicin Market Competitive Landscape
The liposomal doxorubicin market is very capital intensive and dynamic due to the pharmaceutical industry's competitive environment. Additionally, businesses partner and merge with other businesses, which deepens their roots and broadens their manufacturing and distribution capabilities. In order to boost growth, consumer base, and market position globally, several firms have used business tactics like the introduction of new products, the development of technologies, partnerships, mergers, and the increase of production capacity. Johnson & Johnson unveiled the first doxil ever.
Liposomal Doxorubicin Market Top Player's Company Profiles
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Celsion Corporation
- Gilead Sciences, Inc.
- Eisai Co., Ltd.
- Ligand Pharmaceuticals
- Sandoz (a division of Novartis)
- Eagle Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Ltd.
- Pacira BioSciences, Inc.
- Formosa Laboratories, Inc.
- Intas Pharmaceuticals Ltd.
- Zydus Cadila
- TTY Biopharm
- Luye Pharma Group Ltd.
- CP Pharmaceuticals Ltd.
- Actavis (now part of Teva)
- Ipsen S.A.
Liposomal Doxorubicin Market Recent Developments
-
In January 2024, Natco Pharma Limited finalized the combination of DASH Pharmaceuticals into Natco Pharma USA, reinforcing its essential foothold in the US.
-
In December 2023, Quest Diagnostics' subsidiary, Haystack Oncology, collaborated with Rutgers Cancer Institute of New Jersey to use Haystack MRD technology in a clinical report focusing on the beginning phase of triple-negative breast cancer. Rutgers Cancer Institute, as a team with RWJBarnabas Health, is New Jersey's only Comprehensive Cancer Center recognized by the National Cancer Institute.
-
In November 2023, Verastem Oncology shared financial outcomes for the third quarter, finishing September 30, 2023, and framed ongoing advancements. They featured promising information from a subgroup analysis of the RAMP 201 study, areas of strength for showing levels of avutometinib and defactinib. This supports their true capacity as therapy choices for LGSOC (low-grade serous ovarian cancer), independent of a patient's earlier treatment.
Liposomal Doxorubicin Key Market Trends
- Breast cancer is the most frequent cancer treated with doxorubicin, even though it is used to treat a variety of malignancies. The International Agency for Research on Cancer (IARC) reported in December 2020 that 1 in 4 cancer diagnoses in women worldwide are breast cancer cases.
- According to a World Health Organization article from April 2021, there were 2.3 million women diagnosed with breast cancer in 2020, and there were 685,000 fatalities worldwide. By 2020, 7.8 million women will have received a breast cancer diagnosis, making it the most common cancer worldwide. According to the American Cancer Institute, Doxorubicin is a chemotherapy medication used to treat advanced breast cancer.
Liposomal Doxorubicin Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.
According to our global liposomal doxorubicin market analysis, the market is going to witness a healthy growth during the forecast period because of an increase in cases of cancer and increased cost of medication. A further factor driving the market's expansion is the general public's growing awareness of the cancer treatment options that are accessible. Additional growth-promoting developments include the creation of archetypal nanodrugs and better chemotherapeutic medicines. These developments make it easier to administer drugs to precise locations and release them slowly into the body.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 1.27 billion |
| Market size value in 2031 | USD 2.16 billion |
| Growth Rate | 6.1% |
| Base year | 2023 |
| Forecast period | 2024- 2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Liposomal Doxorubicin Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Liposomal Doxorubicin Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Liposomal Doxorubicin Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Liposomal Doxorubicin Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Liposomal Doxorubicin Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Liposomal Doxorubicin Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
